U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274085) titled 'A Phase 1 Study of HDM2017 in Advanced Solid Tumors' on Nov. 24.
Brief Summary: This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of HDM2017 in patients with advanced malignant solid tumors.
Study Start Date: Nov. 18
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: HDM2017
Participants will be treated with HDM2017 intravenous infusion
Recruitment Status: RECRUITING
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd....